Vertex Pharmaceuticals, Pfizer, Eli Lilly and Company, D-Wave Quantum, and Novo Nordisk A/S are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture and market prescription drugs and medical therapies. Their market value is often driven by factors such as clinical-trial outcomes, regulatory approvals or setbacks, patent expirations and shifts in healthcare policy. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of VRTX traded down $90.56 during mid-day trading on Tuesday, hitting $381.71. The stock had a trading volume of 7,230,139 shares, compared to its average volume of 1,563,805. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The company has a quick ratio of 2.29, a current ratio of 2.65 and a debt-to-equity ratio of 0.01. The company has a market cap of $98.02 billion, a PE ratio of -97.41 and a beta of 0.44. The company's fifty day simple moving average is $456.34 and its two-hundred day simple moving average is $467.46.
Read Our Latest Research Report on VRTX
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
PFE traded up $1.26 on Tuesday, hitting $24.79. 77,494,356 shares of the company's stock were exchanged, compared to its average volume of 45,672,621. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The stock has a fifty day moving average of $24.37 and a two-hundred day moving average of $24.53. Pfizer has a twelve month low of $20.92 and a twelve month high of $30.43. The firm has a market cap of $140.91 billion, a PE ratio of 17.95, a P/E/G ratio of 0.85 and a beta of 0.52.
Read Our Latest Research Report on PFE
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
NYSE LLY traded down $3.94 during trading hours on Tuesday, hitting $765.06. The company had a trading volume of 1,342,521 shares, compared to its average volume of 3,787,935. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The firm has a market cap of $725.08 billion, a P/E ratio of 62.26, a price-to-earnings-growth ratio of 1.08 and a beta of 0.44. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The business has a fifty day simple moving average of $776.59 and a 200-day simple moving average of $800.81.
Read Our Latest Research Report on LLY
D-Wave Quantum (QBTS)
D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.
NYSE QBTS traded up $1.10 on Tuesday, hitting $18.28. The stock had a trading volume of 47,125,835 shares, compared to its average volume of 69,582,109. The company's 50-day moving average is $16.66 and its two-hundred day moving average is $10.85. D-Wave Quantum has a one year low of $0.75 and a one year high of $20.56. The stock has a market cap of $5.34 billion, a price-to-earnings ratio of -30.46 and a beta of 1.41. The company has a quick ratio of 20.61, a current ratio of 20.73 and a debt-to-equity ratio of 0.15.
Read Our Latest Research Report on QBTS
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Shares of NVO traded down $1.42 during trading hours on Tuesday, reaching $47.39. 15,767,047 shares of the company's stock traded hands, compared to its average volume of 10,819,526. The business's fifty day simple moving average is $68.89 and its two-hundred day simple moving average is $72.37. The firm has a market capitalization of $211.61 billion, a price-to-earnings ratio of 14.00, a P/E/G ratio of 1.46 and a beta of 0.63. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. Novo Nordisk A/S has a twelve month low of $46.90 and a twelve month high of $139.74.
Read Our Latest Research Report on NVO
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
